Venous thromboembolism in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with lenalidomide: a systematic review

References

• Aguiar PM, de Mendonça Lima T, et al. Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: an overview of systematic reviews with meta-analyses. Crit Rev Oncol Hematol. 2017;113:195–212.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Bohlke K, Khorana AA, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline update 2014. JCO. 2015;33:654–656.
   PubMed Web of Science ®Google Scholar
• Ujjani CS, Jung SH, Pitcher B, et al. Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: alliance A051103. Blood. 2016;128:2510–2516.
   PubMed Web of Science ®Google Scholar
• Smith SM, Pitcher BN, Jung SH, et al. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. Lancet Haematol. 2017;4:e176–e182.
   PubMed Web of Science ®Google Scholar
• Martin P, Jung SH, Pitcher B, et al. A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance). Ann Oncol. 2017;28:2806–2812.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Tilly H, Gomes da Silva M, et al. Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. JCO. 2017;35:2473–2481.
   PubMed Web of Science ®Google Scholar
• Rosenthal A, Dueck AC, Ansell S, et al. A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy. Am J Hematol. 2017;92:467–472.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Sassone M, Zaja F, et al. Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial. Lancet Haematol. 2017;4:e137–e146.
   PubMed Web of Science ®Google Scholar
• Zaja F, Ferrero S, Stelitano C, et al. Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi. Haematologica. 2017;102:e203–e206.
   PubMed Web of Science ®Google Scholar
• Mauro FR, Carella AM, Molica S, et al. Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial. Leuk Lymphoma. 2017;58:1640–1647.
   PubMed Web of Science ®Google Scholar
• Reddy NM, Greer JP, et al. A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma. Leukemia. 2017;31:241–244.
   PubMed Web of Science ®Google Scholar
• Ruan J, Martin P, Shah B, et al. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. N Engl J Med. 2015;373:1835–1844.
   PubMed Web of Science ®Google Scholar
• Albertsson-Lindblad A, Kolstad A, Laurell A, et al. Lenalidomide–bendamustine–rituximab in patients older than 65 years with untreated mantle cell lymphoma. Blood. 2016;128:1814–1820.
   PubMed Web of Science ®Google Scholar
• Chang JE, Havighurst T, Kim K, et al. Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: a Wisconsin Oncology Network Study. Br J Haematol. 2016;173:283–291.
   PubMed Web of Science ®Google Scholar
• Trněný M, Lamy T, Walewski J, et al. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. Lancet Oncol. 2016;17:319–331.
   PubMed Web of Science ®Google Scholar
• Ogura M, Imaizumi Y, Uike N, et al. Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose–escalation study. Lancet Haematol. 2016;3:e107–e118.
   PubMed Web of Science ®Google Scholar
• Sacchi S, Marcheselli R, Bari A, et al. Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi. Haematologica. 2016;101:e196–e199.
   PubMed Web of Science ®Google Scholar
• Martín A, Redondo AM, Dlouhy I, et al. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group. Br J Haematol. 2016;173:245–252.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Crawford J. A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas. Br J Haematol. 2015;169:528–533.
   PubMed Web of Science ®Google Scholar
• Chong EA, Ahmadi T, Aqui NA, et al. Combination of lenalidomide and rituximab overcomes rituximab resistance in patients with indolent B-cell and mantle cell lymphomas. Clin Cancer Res. 2015;21:1835–1842.
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, LaPlant B, Macon WR, et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. JCO. 2015;33:251–257.
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, LaPlant B, Habermann TM, et al. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia. 2011;25:1877–1881.
   PubMed Web of Science ®Google Scholar
• Morrison VA, Jung SH, Johnson J, et al. Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). Leuk Lymphoma. 2015;56:958–964.
   PubMed Web of Science ®Google Scholar
• Vitolo U, Chiappella A, Franceschetti S, et al. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. Lancet Oncol. 2014;15:730–737.
   PubMed Web of Science ®Google Scholar
• Feldman T, Mato AR, Chow KF, et al. Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma. Br J Haematol. 2014; 166:77–83.
   PubMed Web of Science ®Google Scholar
• Tuscano JM, Dutia M, Chee K, et al. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma. Br J Haematol. 2014;165:375–381.
   PubMed Web of Science ®Google Scholar
• Hopfinger G, Nösslinger T, Lang A, et al. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial. Ann Hematol. 2014;93:459–462.
   PubMed Web of Science ®Google Scholar
• Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. JCO. 2013;31:3688–3695.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Fitoussi O, Haioun C, et al. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer. 2013;49:2869–2876.
   PubMed Web of Science ®Google Scholar
• Eve HE, Carey S, Richardson SJ, et al. Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. Br J Haematol. 2012;159:154–163.
   PubMed Web of Science ®Google Scholar
• Kiesewetter B, Troch M, Dolak W, et al. A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma). Haematologica. 2013;98:353–356.
   PubMed Web of Science ®Google Scholar
• Tilly H, Morschhauser F, Salles G, et al. Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma. Leukemia. 2013;27:252–255.
   PubMed Web of Science ®Google Scholar
• Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012;13:716–723.
   PubMed Web of Science ®Google Scholar
• Wang M, Fowler N, Wagner-Bartak N, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013;27:1902–1909.
   PubMed Web of Science ®Google Scholar
• Wendtner CM, Hallek M, Fraser GA, et al. Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial. Leuk Lymphoma. 2016;57:1291–1299.
   PubMed Web of Science ®Google Scholar
• Zaja F, De Luca S, Vitolo U, et al. Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica. 2012;97:416–422.
   PubMed Web of Science ®Google Scholar
• Toumishey E, Prasad A, Dueck G, et al. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma. Cancer. 2015;121:716–723.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol. 2009;27:5404–5409.
   PubMed Web of Science ®Google Scholar
• Vitale C, Falchi L, Ten Hacken E, et al. Ofatumumab and lenalidomide for patients with relapsed or refractory chronic lymphocytic leukemia: correlation between responses and immune characteristics. Clin Cancer Res. 2016;22:2359–2367.
   PubMed Web of Science ®Google Scholar
• Badoux XC, Keating MJ, Wen S, et al. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2013;31:584–591.
   PubMed Web of Science ®Google Scholar
• Badoux XC, Keating MJ, Wen S, et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood. 2011;118:3489–3498.
   PubMed Web of Science ®Google Scholar
• Brown JR, Abramson J, Hochberg E, et al. A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL. Leukemia. 2010;24:1972–1975.
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008;111:5291–5297.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006;24:5343–5349.
   PubMed Web of Science ®Google Scholar
• Kiesewetter B, Willenbacher E, Willenbacher W, et al. A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma. Blood. 2017;129:383–385.
   PubMed Web of Science ®Google Scholar
• Querfeld C, Rosen ST, Guitart J, et al. Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome. Blood. 2014;123:1159–1166.
   PubMed Web of Science ®Google Scholar
• Law AD, Prakash G, Khadwal A, et al. L-PROBe: a novel non-anthracycline combination chemotherapy regimen for aggressive B cell non-Hodgkin lymphoma in elderly patients. Indian J Hematol Blood Transfus. 2017;33:61–68.
   PubMed Web of Science ®Google Scholar
• Bagot M, Hasan B, Whittaker S, et al. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma – EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. Eur J Dermatol. 2017;27:286–294.
   PubMed Web of Science ®Google Scholar
• Ishida T, Fujiwara H, Nosaka K, et al. Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia/lymphoma: ATLL-002. J Clin Oncol. 2016;34:4086–4093.
   PubMed Web of Science ®Google Scholar
• Leonard JP, Jung SH, Johnson J, et al. Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance). JCO. 2015;33:3635–3640.
   PubMed Web of Science ®Google Scholar
• Mato AR, Foon KA, Feldman T, et al. Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia. Am J Hematol. 2015; 90:487–492.
   PubMed Web of Science ®Google Scholar
• Fowler NH, Davis RE, Rawal S, et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014;15:1311–1318.
   PubMed Web of Science ®Google Scholar
• Hitz F, Fischer N, Pabst T, et al. Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial. Ann Hematol. 2013;92:1033–1040.
   PubMed Web of Science ®Google Scholar
• Hitz F, Zucca E, Pabst T, et al. Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy – SAKK 38/08. Br J Haematol. 2016;174:255–263.
   PubMed Web of Science ®Google Scholar
• Wendtner CM, Hillmen P, Mahadevan D, et al. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53:417–423.
   PubMed Web of Science ®Google Scholar
• Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. JCO. 2008;26:4952–4957.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol. 2011;22:1622–1627.
   PubMed Web of Science ®Google Scholar
• Strati P, Keating MJ, Burger JA, et al. Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia. Haematologica. 2017;102:e494–e496.
   PubMed Web of Science ®Google Scholar
• James DF, Werner L, Brown JR, et al. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. JCO. 2014;32:2067–2073.
   PubMed Web of Science ®Google Scholar
• Maddocks K, Ruppert AS, Browning R, et al. A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia. Leuk Res. 2014;38:1025–1029.
   PubMed Web of Science ®Google Scholar
• Chen CI, Bergsagel PL, Paul H, et al. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. JCO. 2011;29:1175–1181.
   PubMed Web of Science ®Google Scholar
• Sylvan SE, Rossmann E, Mozaffari F, et al. Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-induced immunosuppression. Br J Haematol. 2012;159:608–612.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Egyed M, Robak T, et al. Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial). Leukemia. 2017;31:1240–1243.
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Trněný M, Davies A, et al. A phase 2/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator's choice in patients with relapsed or refractory diffuse large B-cell lymphoma. Clin Cancer Res. 2017;23:4127–4137.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Pellegrini C, Broccoli A, et al. Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. Leuk Lymphoma. 2011;52:1585–1588.
   PubMed Web of Science ®Google Scholar
• Costa LJ, Fanning SR, Stephenson Jr, et al. Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Leuk Lymphoma. 2015;56:645–649.
   PubMed Web of Science ®Google Scholar
• Maurer C, Pflug N, Bahlo J, et al. Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia. Eur J Haematol. 2016;97:253–260.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Pellegrini C, Gandolfi L, et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk. 2011; 11:462–466.
   PubMed Web of Science ®Google Scholar
• Chiappella A, Tucci A, Castellino A, et al. Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. Haematologica. 2013;98:1732–1738.
   PubMed Web of Science ®Google Scholar
• Chavez JC, Piris-Villaespesa M, Dalia S, et al. Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia. Leuk Res. 2016;47:78–83.
   PubMed Web of Science ®Google Scholar
• Gade IL, Braekkan S, Naess IA, et al. Epidemiology of venous thromboembolism in hematological cancers: The Scandinavian Thrombosis and Cancer (STAC) cohort. Thromb Res. 2017;158:157–160.
   Google Scholar
• De Stefano V, Za T, Rossi E. Venous thromboembolism in multiple myeloma. Semin Thromb Hemost. 2014; 40:338–347.
   PubMed Web of Science ®Google Scholar
• Santi RM, Ceccarelli M, Bernocco E, et al. Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL). Thromb Haemost. 2017 [cited Apr 27]. DOI:10.1160/TH16-11-0895
   PubMed Web of Science ®Google Scholar
• Caruso V, Di Castelnuovo A, Meschengieser S, et al. Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events. Blood. 2010;115:5322–5328.
   PubMed Web of Science ®Google Scholar
• Jin S, Pazdur R, Sridhara R. Re-evaluating eligibility criteria for oncology clinical trials: analysis of investigational new drug applications in 2015. JCO. 2017; 35:3745–3752.
   PubMed Web of Science ®Google Scholar
• Yamshon S, Demetres M, Hammad H, et al. Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma (NHL) treated with lenalidomide. Blood. 2017;130:221.
   PubMedGoogle Scholar